Half-curcumin analogues as PET imaging probes for Amyloid beta species

Abstract:

Evidence suggests that the abnormal levels of Amyloid beta (A) species in brains appear as early as 30 years before symptom starts in Alzheimer’s disease (AD) patients. However, the early generation PET probes can only detect the abnormal A deposits close to the onset of clinical AD syndrome. In this report, we demonstrated that half-curcuminoid could be a better scaffold for PET tracer development. Through blocking a highly reactive site of half-curcuminoids, F-CRANAD-101 was designed and showed significant responses to both soluble and insoluble Aβs in fluorescent spectral tests. PET imaging results indicated that both 14-month and 5-month APP/PS1 AD mice had higher signals in brain than the age-matched wild type mice. We believe that [18F]-CRANAD-101 could be a potential PET imaging probe for Amyloid betas in Alzheimer’s disease.

Publisher's Version

Last updated on 08/16/2020